autologous blood and marrow transplantation - Blog Science ...

Ball et al. 25
Table 2. Factors investigated using proportional hazards regression
Remission status
Conditioning regimen
Age
Age >30
Log 10 BMI
Female sex
FAB
HxMDS
Secondary AML
Hx MDS or secondary AML
Extramedullary disease
Log 10 event to autoBMT
PM81
Log 10 WBC at diagnosis
Abnormal 16q
7q-
+8
t(15;17)
t(8;21)
Normal karyotype
Karyotype prognosis
Length of time in CR1 (CR2/3 patients only)
A median number of 4.0X10 7
RESULTS
Engraftment
cells/kg body weight (range 2.30-8.23X10 7
)
were infused into each CR1 patient. The median number of cells transfused into the
CR2/3 group was 2.80X10 7
4.10X10 7
(range 0.075-1.16X10 8
). A median number of
cells/kg (range 2.38-59.6X10 7
) were infused into each Rl patient.
Median observed recovery time for neutrophils to 500 cells/uL was 33 days.
Median times to reach platelet counts of >20,000 and >50,000/uL independent of
platelet transfusions were 51 and 79 days, respectively.
Disease-free and overall survival
The DFS and OS from transplant of all patients as of 25 September 1997 are
shown in Figures 1-6 by status at transplant (CR1, CR2/3, and Rl).
For patients in CR1 treated with Cy/TBI («=7), 3- and 5-year DFS rates were
71 and 57% (95% CI 38-100% and 20-94%) (Tables 3 and 4). For CR1 patients
treated with BU/Cy («=12), 3- and 5-year DFS rates were both 45% (95% CI